SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
130 hedge funds and large institutions have $3.89B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 19 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 41
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
15% more capital invested
Capital invested by funds: $3.37B → $3.89B (+$513M)
3% more funds holding
Funds holding: 126 → 130 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
68% less call options, than puts
Call options by funds: $21.7M | Put options by funds: $68.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$106M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$102M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.9M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$48.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$48.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$63.7M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$29.7M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$11.1M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$10.8M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$8.23M |
GEVA Hedge Fund Activity: Q1 2015 in Review
130 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q1 2015, worth a combined $3.89B — up 15% from $3.37B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GEVA positions and 19 closed out — a net gain of 4 holders — while 56 added to existing stakes and 41 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $106M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $63.7M.
- 130 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q1 2015, up from 126 in Q4 2014.
- Funds reported $3.89B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q1 2015, up 15% quarter-over-quarter.
- 23 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q1 2015 and 19 closed out, a net change of +4 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q1 2015 was Baker Bros. Advisors, an estimated $106M added.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q1 2015 was Columbia Wanger Asset Management, an estimated $63.7M sold.
Based on aggregated 13F filings for Q1 2015.